Lung Cancer

Liquid biopsies are critical in understanding oncogenic drivers and resistance mechanisms in patients with non–small cell lung cancer.

A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.

Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.

An oncologist reviews the case of a 57-year-old man diagnosed with small cell lung cancer after Lambert-Eaton myasthenic syndrome.

Drs. Steven Vernino and David Gerber continue their conversation on their preferred treatment approaches and monitoring strategies for Lambert-Eaton myasthenic syndrome and small cell lung cancer.

Wade T. Iams, MD, discusses the need to establish the clinical utility of circulating tumor DNA testing in lung cancer.

As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.

The European Commission has granted conditional marketing authorization to sotorasib for the treatment of adult patients with KRAS G12C mutant advanced non–small cell lung cancer.

Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Solange Peters, MD, PhD, and Tony SK Mok, MD, discuss what they’re looking forward to in the future for treating both stages of EGFR mutant NSCLC and give advice to colleagues treating this disease.

Drs Mok and Peters explain the updates seen in the treatment landscape for EGFR mutant advanced-stage NSCLC.

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

One of the reverberating themes of 2021 that should carry into 2022 is the importance of molecular testing.

A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.

CLN-081 continued to produce encouraging, durable responses with favorable safety and tolerability in patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations and who have progressed on or after prior therapy.

The idea to provide wearable devices to my patients first came to me 6 years ago at a charity spinning event.

Mirati Therapeutics and Verastem Oncology have entered a nonexclusive clinical collaboration to evaluate the combination of adagrasib plus VS-6766 for patients with non–small cell lung cancer harboring a KRAS G12C mutation who have progressed on a KRAS G12C inhibitor in a phase 1/2 trial.

The FDA granted a breakthrough therapy designation to telisotuzumab vedotin for use in patients with advanced or metastatic EGFR wild-type, nonsquamous non–small cell lung cancer who have high levels of c-Met overexpression and whose disease has progressed on, or after, platinum-based chemotherapy.

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy.

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Key opinion leaders detail the treatment options available for Lambert-Eaton myasthenic syndrome.

Steven Vernino, MD, describes the first-line treatment options for small cell lung cancer with Lambert-Eaton myasthenic syndrome.

The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.

Tony SK Mok, MD, and Solange Peters, MD, PhD, relay the available treatment options for EGFR mutant NSCLC—both early and advanced stages.

Dr Mok finishes our discussion on the ADAURA trial, and Dr Peters delves into selecting the right adjuvant therapy for a patient with early-stage EGFR mutant NSCLC.

Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.